Interim Analysis of the Phase II Trial of Brentuximab Vedotin in CD30-Positive Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas


Interim Analysis of the Phase II Trial of Brentuximab Vedotin in CD30-Positive Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Andrew M Evens, DO, MSc (2/12/14)
Bartlett NL et al. A Phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: Interim results in patients with DLBCL and other B-cell lymphomas. Proc ASH 2013;Abstract 848.

Dr Evens is Professor of Medicine and Chief of the Division of Hematology/Oncology at Tufts Medical Center and Director of the Lymphoma Program and Interim Director at Tufts Cancer Center in Boston, Massachusetts.